1-9 of 9
Keywords: left heart disease
Sort by
Journal Article
Giovanna Manzi and others
European Heart Journal Supplements, Volume 27, Issue Supplement_1, February 2025, Pages i109–i114, https://doi.org/10.1093/eurheartjsupp/suae092
Published: 19 February 2025
... the development of pulmonary vascular disease with vasoconstriction and remodelling of the pulmonary arterial bed ( Figure 1 ). Figure 1 The best pulmonary hypertension-left heart disease therapeutic approach includes the correction of the underlying substrate, the optimization of heart failure...
Journal Article
Anna Titz and others
European Heart Journal Open, Volume 3, Issue 4, July 2023, oead069, https://doi.org/10.1093/ehjopen/oead069
Published: 03 July 2023
...) is a haemodynamic condition that affects ∼1% of the global population. It may be associated with a variety of cardiovascular and respiratory diseases. Left heart disease (LHD) is the leading cause of PH, and the global burden has doubled from 1990 to 2013. 1 , 2 Pulmonary hypertension is now defined...
Journal Article
GUIDELINES
Marc Humbert and others
European Heart Journal, Volume 43, Issue 38, 7 October 2022, Pages 3618–3731, https://doi.org/10.1093/eurheartj/ehac237
Published: 26 August 2022
... thrombo-embolic pulmonary hypertension Left heart disease Congenital heart disease Lung disease Connective tissue disease Endothelin receptor antagonists Phosphodiesterase type 5 inhibitors Soluble guanylate cyclase stimulators Prostacyclin analogues Prostacyclin receptor agonists Pulmonary...
Journal Article
Kazunori Omote and others
European Heart Journal, Volume 43, Issue 36, 21 September 2022, Pages 3417–3431, https://doi.org/10.1093/eurheartj/ehac184
Published: 07 July 2022
... 28 03 2022 Corresponding author. Tel: +1 507 284 4442, Fax: +1 507 266 0228, Email: [email protected] Conflict of interest: none declared. Left heart disease (LHD) is the most common cause of pulmonary hypertension (PH). 1–5 While PH-LHD is initially caused by passive...
Journal Article
Quang T Nguyen and others
Cardiovascular Research, Volume 116, Issue 1, 1 January 2020, Pages 171–182, https://doi.org/10.1093/cvr/cvz034
Published: 07 February 2019
... therapies specifically targeting PH and lung remodelling associated with left heart diseases (LHD). PBI-4050 (3-pentylbenzeneacetic acid sodium salt) is an orally active fatty acid (FA) synthetic analogue derived from decanoic acid. 6 PBI-4050 is a modulator of the G protein-coupled receptors...
Journal Article
EDITOR'S CHOICE GUIDELINES
Nazzareno Galiè and others
European Heart Journal, Volume 37, Issue 1, 1 January 2016, Pages 67–119, https://doi.org/10.1093/eurheartj/ehv317
Published: 29 August 2015
... international normalized ratio IPAH idiopathic pulmonary arterial hypertension Ipc-PH isolated post-capillary pulmonary hypertension IPF idiopathic pulmonary fibrosis i.v. intravenous IVC inferior vena cava LA left atrium/atrial LHD left heart disease LV left...
Chapter
Published: 01 February 2015
..., according to the clinical group, and symptomatic and haemodynamic severity. For these reasons, the four more frequent clinical groups are discussed individually, while the classifications are described in the Introduction section. pulmonary hypertension heart failure left heart disease parenchymal lung...
Chapter
Published: 01 July 2018
...European Society of Cardiology Pulmonary hypertension is a common complication of left heart diseases. Although it may be encountered in all disorders, pulmonary hypertension in left heart disease is most common in heart failure with preserved or reduced ejection fraction. When present, pulmonary...
Chapter
Published: 01 February 2021
... clinical groups are discussed individually, while the classifications are described in the Introduction section. pulmonary hypertension heart failure left heart disease parenchymal lung disease pulmonary embolism pulmonary hypertension PH echocardiography pulmonary arterial hypertension PAH...